Ekkehard Schütz
Technik-/Wissenschafts-/F&E-Leiter bei ONCOCYTE CORPORATION
Vermögen: - $ am 30.04.2024
Profil
Ekkehard Schütz is currently the Chief Executive Officer & Chief Medical Officer at Chronix Biomedical, Inc. He is also the Managing Director at Chronix Biomedical GmbH since 2011.
Additionally, he holds the position of Chief Science Officer at OncoCyte Corp.
starting from 2021.
Dr. Schütz obtained his doctorate degree from the University of Gottingen.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
ONCOCYTE CORPORATION
-.--% | 29.04.2024 | 0 ( -.--% ) | - $ | 30.04.2024 |
Aktive Positionen von Ekkehard Schütz
| Unternehmen | Position | Beginn |
|---|---|---|
| ONCOCYTE CORPORATION | Technik-/Wissenschafts-/F&E-Leiter | 01.04.2021 |
Chronix Biomedical, Inc.
 Chronix Biomedical, Inc. Medical SpecialtiesHealth Technology Chronix Biomedical, Inc. manufactures diagnostic substances chemicals. It develops DNA-based blood tests primarily for monitoring minimal residual disease in cancer patients. The firm also develops a technology that measures personalized biomarkers in cancers of the colorectum, prostate, lung, ovarian, pancreas, blood and central nervous system. The company was founded by Wiiliam A. Boeger and Howard B. Urnovitz in 1997 and is headquartered in San Jose, CA. | Vorstandsvorsitzender | - |
| Chronix Biomedical GmbH | Corporate Officer/Principal | 01.04.2011 |
Ausbildung von Ekkehard Schütz
| University of Gottingen | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| ONCOCYTE CORPORATION | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Chronix Biomedical, Inc.
Chronix Biomedical, Inc. Medical SpecialtiesHealth Technology Chronix Biomedical, Inc. manufactures diagnostic substances chemicals. It develops DNA-based blood tests primarily for monitoring minimal residual disease in cancer patients. The firm also develops a technology that measures personalized biomarkers in cancers of the colorectum, prostate, lung, ovarian, pancreas, blood and central nervous system. The company was founded by Wiiliam A. Boeger and Howard B. Urnovitz in 1997 and is headquartered in San Jose, CA. | Health Technology |
| Chronix Biomedical GmbH |
